ArticleClinical and molecular hepatology2026
Optimized MASH treatment eligibility cutoffs for MRE-measured liver stiffness and proton density fat fraction.
Nana Owusu, Kyle Kalutkiewicz, Jiahui Li, Alina M Allen, Rohit Loomba, Richard L Ehman, Meng Yin
Abstract read
In one paragraphArticle in Clinical and molecular hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Nana OwusuDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Kyle KalutkiewiczResoundant Inc., Rochester, MN, USA.
Jiahui LiDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Alina M AllenDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Rohit LoombaDivision of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, CA, USA.
Richard L EhmanDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Meng YinDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Funding
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3MPediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4MTissue-specific roles of FXR in CVD and NASHP01HL147835 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2024
$12.2MSan Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8MMULTIDISCRIPLINARY TRAINING IN DIGESTIVE DISEASEST32DK007198 · NIDDK · MAYO CLINIC ROCHESTER · PI Harmeet Malhi · 1986 to 2026
$8.9MHIV MASLD Clinical Research Network (HCRN)R01DK121378 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI NAGA P CHALASANI, ROHIT LOOMBA · 2020 to 2026
$8.7MComprehensive noninvasive assessment of liver histopathology in nonalcoholic fatty liver disease (NAFLD) via magnetic resonance imaging, cytometry and elastography (MR-ICE)R01EB017197 · NIBIB · MAYO CLINIC ROCHESTER · PI YIN, MENG · 2014 to 2025
$4.3MMagnetic Resonance ElastographyR37EB001981 · NIBIB · MAYO CLINIC ROCHESTER · PI EHMAN, RICHARD L. · 2016 to 2025
$4.0MQUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLDR01DK106419 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT, SIRLIN, CLAUDE B · 2015 to 2019
$3.4MNon-invasive screening of diabetics for advanced fibrosis due to NAFLDR01DK124318 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2022
$1.7MNAFLD Diagnosis and OutcomesR01DK134448 · NIDDK · MAYO CLINIC ROCHESTER · PI Alina M Allen · 2024 to 2026
$1.5MMidwest DDRCC Alliance Conference (Hosted by the Mayo Clinic DDRCC)R13DK136181 · NIDDK · MAYO CLINIC ROCHESTER · PI LARUSSO, NICHOLAS F. · 2023 to 2023
$22kArrowhead PharmaceuticalsAstraZenecaBoehringer-IngelheimBristol-Myers SquibbDigestive Disease Research Core Center P30DK120515Digestive Disease Research Core Center R01DK106419Digestive Disease Research Core Center R01DK121378Digestive Disease Research Core Center R01DK124318Digestive Disease Research Core Center R13DK136181Digestive Disease Research Core Center R13DK142549Digestive Disease Research Core Center U01DK061734Digestive Disease Research Core Center U01DK130190Eli LillyEscopicsGalectin TherapeuticsGalmed PharmaceuticalsGileadHanmiInterceptInventivaIonisJanssenMadrigalMadrigal PharmaceuticalsMerckNCATS NIH HHS 5UL1TR001442NCATS NIH HHS UL1 TR001442NGM BiopharmaceuticalsNHLBI NIH HHS P01 HL147835NHLBI NIH HHS P01HL147835NIBIB NIH HHS R01 EB017197NIBIB NIH HHS R37 EB001981NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK106419NIDDK NIH HHS R01 DK121378NIDDK NIH HHS R01 DK124318NIDDK NIH HHS R01 DK134448NIDDK NIH HHS R13 DK136181NIDDK NIH HHS R13DK136181NIDDK NIH HHS R13DK14254NIDDK NIH HHS R13 DK142549NIDDK NIH HHS T32 DK007198NIDDK NIH HHS T32DK007198NIDDK NIH HHS U01 DK061734NIH HHS NIBIB R01 EB017197NIH HHS NIBIB R37 EB001981Novo NordiskOncousticsPfizerSiemensSonic IncytesTarget PharmaTerns Pharmaceuticals
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Biomarker optimizationFibrosis stageResmetiromSemaglutideTreatment eligibility
Identifiers
PMID41360082
PMCPMC12835756
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390